Tag: Cancer: Rectal
ACP: Screening Average-Risk Adults for Colorectal Cancer Should Start at 50 Years
For asymptomatic average-risk adults, clinicians should consider not screening at age 45 to 49 years, according to ACP
Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
Significantly improved overall survival seen with fruiquintinib versus placebo, with favorable safety profile
Risk Factors Identified for Early-Onset Sporadic Colorectal Cancer
Independent risk factors include age, body mass index, comorbidity, first- or second-degree relative with CRC, alcohol use
Doubling Up on FIT Testing Catches More Colorectal Cancers
Two-test strategy has sensitivity of 96.6 percent versus 84.1 percent for single-test strategy
Locally Recurrent Rectal Cancer QoL Is Valid Patient-Reported Outcome Measure
LRRC-QoL consisted of nine multi-item scales and three single items; has convergent validity with other measures
ASCO: FOLFOX Noninferior to Chemoradiotherapy for Overall Survival in Rectal Cancer
Findings seen in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery
ASCO: Microbiome Varies for Early-Onset, Late-Onset Colorectal Cancer
Cladosporium sp. was more commonly found in early-onset CRC, while Pseudomonas luteola, Ralstonia sp., Moraxella osloensis occurred more often in late-onset CRC
Red-Flag Signs May Indicate Early-Onset Colorectal Cancer
Abdominal pain, rectal bleeding, diarrhea, and iron deficiency anemia seen up to two years before diagnosis
Overweight, Obesity in Early, Middle Adulthood Increases Risk for GI Cancers
Risk not reduced with aspirin use three or more times per week for colorectal and noncolorectal cancers
FTD-TPI Plus Bevacizumab Increases Survival in Refractory Advanced CRC
Significantly longer overall survival and progression-free survival seen for combination versus TFD-TPI alone
